Mission Remission: Are there pathways to remission when combination therapy is not appropriate?
A Roche Products Ltd / Chugai Pharma UK Ltd Sponsored Symposium
Wednesday 30 April 17.30 - 19.30
Room 3A
Chair: Professor Ernest Choy, Cardiff University School of Medicine, Cardiff, UK
Aim: To examine the different pathways for achieving remission when combination therapy is not appropriate
Outcome 1: Delegates will be able to identify treatment pathways for patients with rheumatoid arthritis who cannot or will not continue to take methotrexate
Outcome 2: Delegates will have a better understanding of the immunological pathways underlying rheumatoid arthritis and how biologic therapies work in this condition
Outcome 3: Delegates will have a better understanding of the efficacy and safety profiles of biologic therapies when used without concurrent methotrexate
Click here for prescribing information
This symposium is sponsored by Roche Products Ltd and Chugai Pharma UK Ltd.
As well as discussing wider aspects of rheumatoid arthritis care, the symposium will contain promotional elements making reference to RoACTEMRA® (tocilizumab).
Mission Remission is initiated and funded by Roche Products Ltd and Chugai Pharma UK Ltd.
Date of Preparation: December 2013; RCUKACTE01040